2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 243-245
Technology and Procedures, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Gene Therapy, Non-Biological Therapies, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Young Adult
PAPER

332 Effect of hematopoietic cell transplantation on organ complications in adults with sickle cell disease: A prospective propensity-matched cohort study

Maud Zwolsman, MD, Elisabeth Dovern, MD, PhD2, Bader Alahmari, MD3, Mazin Ahmed4, Amaria Vledder5, Mohammed Bakkar6, Zoha Zakir7, Elisabeth Suijk8, Charlotte F.J. van Tuijn9, rasha Taher10, tahani Alanazi11, Rahaf Salem12, Husam AlSadi13, Ayman Almozaini14, Bart J. Biemond, MD, PhD15, Mohsen Alzahrani Sr, MD16, Erfan Nur, MD, PhD17
1 Amsterdam University Medical Center, Amsterdam, Netherlands, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands
2 Amsterdam University Medical Center, Amsterdam, Netherlands, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands
3 King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
4 King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
5 Amsterdam University Medical Center, Amsterdam, Netherlands
6 King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
7 King Abdulaziz Medical City, Riyadh, Saudi Arabia
8 Amsterdam University Medical Center, Amsterdam, Netherlands
9 Amsterdam University Medical Center, Amsterdam, Netherlands
10 King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
11 King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
12 King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
13 King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
14 King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
15 Amsterdam University Medical Center, Amsterdam, Netherlands
16 King Abdulaziz Medical City, Riyadh, Saudi Arabia, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
17 Amsterdam University Medical Center, Amsterdam, Netherlands, Sanquin Research and Landsteiner Laboratory, Amsterdam, Netherlands

Background

Improvements in conditioning regimens have resulted in allogeneic hematopoietic cell transplantation (HCT) increasingly being used as curative therapy for adults with sickle cell disease (SCD) despite pre-existing SCD-related organ dysfunction. Although crucial for informed decision making, a systematic long-term evaluation of the effect of HCT on organ dysfunction in adults with SCD is lacking. While abrogating hemolysis and vaso-occlusion may stabilize or improve SCD-related organ damage, transplant-related toxicity could result in further progression or even provoke new organ damage.

Aims

This study aims to systematically assess the long-term effect of HCT on SCD-related complications in adults with SCD. Primary objective was to evaluate the effect of HCT on heart, lung and kidney function, as compared to propensity-matched non-transplant SCD patients. Secondary objectives included the effects of HCT on vaso-occlusive episodes (VOE), avascular osteonecrosis (AVN), retinopathy, and priapism.

 

Methods

This prospective cohort study included adults with SCD undergoing nonmyeloablative matched sibling donor (alemtuzumab/TBI) or reduced intensity (including thiotepa and post-transplant cyclophosphamide) haploidentical HCT at Amsterdam UMC (Amsterdam, Netherlands) and King Abdulaziz Medical City (Riyadh, Saudi Arabia). SCD-related organ dysfunction was evaluated at baseline and annually after HCT, with the frequency of evaluation varying by organ system. This included echocardiography, spirometry, kidney function, retinopathy evaluation, and incidence of VOE, AVN, priapism, and GvHD. Only patients with ≥1 year follow-up are reported here. Propensity score matching with a caliper of 0.2 (age, genotype, annual rate of VOE requiring hospital visit, and number of organs involved) was used to match transplant patients to non-transplant SCD control patients. All control patients met HCT eligibility criteria as of January 1, 2021, with organ function data collected as part of routine clinical care until June 30, 2026. For both cardiac and kidney function, the change (Δ) in each parameter from baseline to longest available follow-up was calculated per patient and compared between transplant and non-transplant cohorts using the Mann-Whitney U test. Lung function was assessed within the transplant group only (n=57), comparing baseline with longest available post-transplant follow-up. Annual VOE rate, AVN, retinopathy, and priapism were reported as incidence during follow-up.

 

Results

After matching, 39 HCT patients (51% male; median age 27 years [range 18-55]; 64.1% HLA-identical, 35.9% haploidentical; median follow-up 49 months [range 15-100]) and 100 controls were included (≈1:3 matching, overall standardized mean difference 0.015). Transplant patients had significant improvements in tricuspid regurgitant jet velocity (TRJV; -0.12 vs +0.01 m/s, p<0.01), tricuspid annular plane systolic excursion (TAPSE; -0.49 vs +0 cm, p<0.001), and left ventricular internal dimension in diastole (LVIDD; -0.28 vs +0.01 cm, p<0.001) compared to controls. Estimated glomerular filtration rate (eGFR) as a measure of kidney function decreased significantly in transplant recipients compared to controls (-9.6 vs -3.8 mL/min/1.73m2, p<0.01), while maintaining a median eGFR of >115 mL/min/1.73m2. A mild increase of proteinuria was observed in both cohorts (+1.53 vs +1.6 mg/mmol, respectively, p=0.87). Forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) increased after transplantation as compared to baseline (FVC: 84 vs 82.3%, p<0.05, and FEV1: 82.9 vs 82% of predicted, p<0.5, respectively), with a slight trend towards decrease in corrected diffusion capacity (DLCOc; 73.5 vs 77.5% of predicted, p=0.2). No VOE, new onset osteonecrosis, priapism, or progression of retinopathy occurred in transplant recipients. No grade III/IV acute GvHD was observed, while 9 patients (15.8%) developed moderate chronic GvHD.

 

Conclusion

This study shows that HCT results in improvement or stabilization of SCD-related organ dysfunction and resolution of VOE and priapism, compared to matched SCD patients as controls. The observed favorable cardiac changes likely reflect normalization of the hyperdynamic state and cardiac remodeling. While the mild decrease in eGFR could reflect resolution of previous hyperfiltration rather than kidney damage, the effect of transplantation on kidney function still warrants further investigation.

Maud Zwolsman, MD: No relevant conflicts of interest to declare.